Health Diagnostic Laboratory, Inc. and Global Genomics Group join forces to form a new scientific process

Sat Jan 26, 2013 10:37pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

RICHMOND, Va.,  Jan. 26, 2013  /PRNewswire/ -- Health Diagnostic Laboratory,
Inc. (HDL, Inc.) is pleased to announce the formation of a strategic alliance
with Global Genomics Group (G3), which aims to detect human susceptibility to
cardiovascular disease through the discovery of genetic biomarkers. G3 and HDL,
Inc. will create a new scientific process that uses advanced imaging to measure
biological information.

Global Genomics Group, founded by Szilard Voros, MD, FACC, FSCCT, FAHA; Idean
Marvasty; and  Brad Brown, MS; and  Jeff Lamkin, has placed itself in the center
of the realm of cardiac biomarkers-one of the fastest growing areas of the
clinical diagnostic market. G3 is a privately held life sciences company focused
on a mission to discover "novel therapeutic and diagnostic targets for
atherosclerotic disease."  

"We focus our research around how human genetic variation affects heart disease
risk. Our solution is to tie the use of advanced imaging to genetics and
genomics-which will lead to more telling and innovative discoveries for the
cardiovascular therapeutic market," said Voros, G3's CEO and co-founder.

Major pharmaceutical companies are shifting their research and development focus
and are partnering with private sector companies such as G3 to help create
innovation and target discovery in the area of cardiovascular therapies for the
pharmaceutical industry.

"HDL, Inc.'s strategic joint venture with Global Genomics Group is inspiring,"
said  Tonya Mallory, CEO and co-founder of HDL, Inc. "Together, we will increase
innovation and discoveries at HDL, Inc. and be able to impact and save more
patients' lives."  

SOURCE  Health Diagnostic Laboratory, Inc.

Paul Spicer of Health Diagnostic Laboratory, +1-804-503-9231,

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.